Table 3.
Comparison of retrospective and prospective studies on Bendamustine and rituximab
| Study (references) | Country | N | Median age (years) | ORR (%) | CR (%) | Median PFS (months) | Grade ¾ hematological toxicity (%) anemia/neutropenia/thrombocytopenia | Cutaneous toxicity all grade (%) |
|---|---|---|---|---|---|---|---|---|
| Fischer et al. [9] | Germany | 117 | 64 | 88 | 23.1 | 33.8 | 19.7/19.7/22.2 | n/a |
| Laurenti et al. [21] | Italy | 70 | 72 | 88.6 | 31.4 | 31.4 | 2/20/4 | 3 |
| Gentile et al. [20] | Italy | 279 | 70 | 86.4 | 28 | 28 | 15.9/25.9/15.4 | 15.9 |
| Špaček et al. [26] | Czech Republic | 83 | 71 | 88 | 20.5 | 20.5 | 9.6/48.2/16.9 | 7.2 |
| Panovska et al. [11] | Czech Republic | 257 | 70.5 | 85.2 | 47.5 | 37 (EFS) | 11.7/49.4/7.8 | n/a |
| Tejaswi et al. [17] | India | 57 | 61 | 91.2 | 77.2 (CRu) | NR | 14/52.6/5.2 | n/a |
| Present study | India | 120 | 57 | 90 | 45 | 24 (EFS) | 12/30.6/8 | 30 |
N Number of patients, ORR Overall response rate, CR Complete response, PFS Progression free survival, EFS Event free survival